Hormonal
Semaglutide (1 mg) promotes significant weight loss and improves BMI in patients without Type 2 Diabetes, without causing significant changes in HbA1c or hypoglycemia risk.
If you do not have diabetes but struggle with weight, semaglutide (1 mg weekly) can help you lose about 3-4% of your body weight. Because it works based on blood sugar levels, it does not typically cause dangerous low blood sugar (hypoglycemia) in non-diabetics. It is used off-label for this purpose but is supported by clinical guidelines.
In the nondiabetic group, the median weight loss was 3 kg (3.4%)... semaglutide significantly promoted weight loss and improved BMI without any significant change in glycemic control, mitigating any risk of hypoglycemia.
Why this rating
Retrospective observational study, no control group, but large sample size (n=332 non-diabetics).
Source
Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia
Muhammad Imran Butt et al. · Annals of Saudi Medicine · 2024
DOI 10.5144/0256-4947.2024.361
More from this paper
- Once-weekly subcutaneous semaglutide (1 mg) produces clinically significant weight loss (median 4.4% in diabetics, 3.4% in non-diabetics) and improves glycemic control (HbA1c reduction of 0.4%) in patients with type 2 diabetes over 6 months.Moderate
- Semaglutide improves cardiometabolic risk factors, including diastolic blood pressure, in patients without diabetes, while maintaining renal stability in both diabetic and non-diabetic populations.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →